ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GTX Genetix Grp

84.00
0.00 (0.00%)
21 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Genetix Grp LSE:GTX London Ordinary Share GB0001276863
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 84.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Presenting at Piper Jaffray European Conference

19/06/2009 7:00am

UK Regulatory



 

TIDMGTX 
 
RNS Number : 1443U 
Genetix Group PLC 
19 June 2009 
 

Genetix Group plc 
 
 
Presenting at Piper Jaffray European Conference 
 
 
 
 
New Milton, UK, 19 June 2009 - Genetix Group plc (AIM:GTX) ("Genetix" or the 
"Company"), the cell imaging and analysis group, today announces that its Chief 
Executive Officer, Charles de Rohan, will be presenting at the Piper Jaffray 
Fourth Annual European Conference in London on 24 June 2009. A webcast of the 
presentation will be available at www.genetix.com following the conference. 
 
 
 
 
=-Ends-- 
 
 
Genetix Group plc 
Charles de Rohan, Chief Executive 
Andrew Kellett, Finance Director 
Tel: +44 (0) 1425 624600 
 
 
Financial Dynamics 
Jonathan Birt; Susan Quigley Tel: +44 (0) 20 7831 3113 
 
 
Piper Jaffray Ltd 
James Steel; Tel: +44 (0) 20 3142 8700 
 
 
 
 
The release will be available on the Company's website: www.genetix.com 
 
 
Notes to Editors 
About Genetix Group plc 
Headquartered in New Milton, UK, with offices in the UK, US, Germany and Japan, 
and quoted on the AIM (GTX: AIM), Genetix provides scientists and clinicians 
with unrivalled solutions for imaging and intelligent image analysis in the life 
science and diagnostic markets. 
 
 
In life sciences, the company's systems set industry standards for accurate 
selection of microbial colonies, and for screening and selection of mammalian 
secretory cell lines. Other systems evaluate the response of cells to potential 
therapeutic agents and quantify tissue biomarkers. 
 
 
In diagnostics, Genetix holds a leading position in genetic testing with 
thousands of the company's platforms used in laboratories worldwide. 
 
 
Through its expertise in robotics, cell and molecular biology, image analysis 
and interpretation, supported by a strong IP portfolio, Genetix is committed to 
the continual development of innovative solutions. 
 
 
 
 
 
 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCILFSSRIITLIA 
 

1 Year Genetix Grp Chart

1 Year Genetix Grp Chart

1 Month Genetix Grp Chart

1 Month Genetix Grp Chart